S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
pixel
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
pixel
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
pixel
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
pixel
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
pixel
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
pixel
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
What to Expect from the Markets in a Recession
pixel
China July exports rise, with trade surplus at record-high
What's in Democrats' big bill? Climate, health care, savings
Shift in war's front seen as ships cleared to leave Ukraine
pixel
Demand for grocery delivery cools as food costs rise
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
NASDAQ:XERS

Xeris Biopharma - XERS Stock Forecast, Price & News

$1.67
+0.07 (+4.38%)
(As of 08/5/2022 08:49 PM ET)
Add
Compare
Today's Range
$1.57
$1.69
50-Day Range
$1.37
$2.26
52-Week Range
$1.25
$3.17
Volume
710,300 shs
Average Volume
1.87 million shs
Market Capitalization
$226.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.13

Xeris Biopharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
266.8% Upside
$6.13 Price Target
Short Interest
Healthy
7.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.57
Upright™ Environmental Score
News Sentiment
1.55mentions of Xeris Biopharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$140,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.83) to ($0.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

277th out of 1,283 stocks

Pharmaceutical Preparations Industry

115th out of 615 stocks

XERS stock logo

About Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Wall Street Analyst Weigh In

Separately, Craig Hallum initiated coverage on shares of Xeris Biopharma in a report on Thursday, April 28th. They set a "buy" rating and a $6.50 price objective on the stock.

Xeris Biopharma Price Performance

Shares of Xeris Biopharma stock opened at $1.67 on Monday. The company has a debt-to-equity ratio of 1.43, a quick ratio of 2.42 and a current ratio of 2.67. The firm's 50-day simple moving average is $1.69 and its 200-day simple moving average is $2.13. Xeris Biopharma has a twelve month low of $1.25 and a twelve month high of $3.17. The firm has a market cap of $226.34 million and a P/E ratio of -1.14.

Xeris Biopharma (NASDAQ:XERS - Get Rating) last issued its earnings results on Wednesday, May 11th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.01). Xeris Biopharma had a negative net margin of 217.81% and a negative return on equity of 258.57%. The business had revenue of $22.07 million for the quarter, compared to analyst estimates of $22.92 million. As a group, research analysts expect that Xeris Biopharma will post -0.83 EPS for the current fiscal year.

Insider Transactions at Xeris Biopharma

In other Xeris Biopharma news, insider Paul R. Edick purchased 100,000 shares of the company's stock in a transaction that occurred on Thursday, May 12th. The stock was acquired at an average cost of $1.40 per share, with a total value of $140,000.00. Following the completion of the purchase, the insider now directly owns 1,508,064 shares in the company, valued at approximately $2,111,289.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 5.17% of the stock is owned by company insiders.

Receive XERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter.

XERS Stock News Headlines

Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings Inc.
Xeris Biopharma spikes as CEO buys company shares
10 Stocks I'm Watching in 2022: An Update
Xeris Pharmaceuticals Q4 2021 Earnings Preview
See More Headlines
Receive XERS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter.

XERS Company Calendar

Last Earnings
5/11/2022
Today
8/07/2022
Next Earnings (Confirmed)
8/10/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XERS
Fax
N/A
Employees
294
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.13
High Stock Price Forecast
$6.50
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+266.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-122,720,000.00
Net Margins
-217.81%
Pretax Margin
-218.45%

Debt

Sales & Book Value

Annual Sales
$49.59 million
Book Value
$1.43 per share

Miscellaneous

Free Float
128,524,000
Market Cap
$226.34 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Paul R. Edick (Age 66)
    Chairman & CEO
    Comp: $1.27M
  • Mr. John P. Shannon (Age 60)
    Pres & COO
    Comp: $966.64k
  • Ms. Beth P. Hecht J.D. (Age 58)
    Chief Legal Officer & Corp. Sec.
    Comp: $662.99k
  • Dr. Steven J. Prestrelski MBA (Age 58)
    Ph.D., Co-Founder & Chief Scientific Officer
  • Mr. Steven M. Pieper (Age 45)
    Chief Financial Officer
  • Ms. Allison Wey
    Sr. VP of Investor Relations & Corp. Communications
  • Dr. Kenneth E. Johnson Pharm. D. (Age 59)
    Pharm.D., Sr. VP of Global Devel. & Medical Affairs
  • Mr. Kevin McCulloch
    Sr. VP of Global Operations & Bus. Devel.













XERS Stock - Frequently Asked Questions

Should I buy or sell Xeris Biopharma stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xeris Biopharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Xeris Biopharma stock.
View analyst ratings for Xeris Biopharma
or view top-rated stocks.

What is Xeris Biopharma's stock price forecast for 2022?

4 Wall Street research analysts have issued 12-month price targets for Xeris Biopharma's shares. Their XERS stock forecasts range from $6.00 to $6.50. On average, they predict Xeris Biopharma's stock price to reach $6.13 in the next year. This suggests a possible upside of 266.8% from the stock's current price.
View analysts' price targets for Xeris Biopharma
or view top-rated stocks among Wall Street analysts.

How has Xeris Biopharma's stock performed in 2022?

Xeris Biopharma's stock was trading at $2.93 at the start of the year. Since then, XERS shares have decreased by 43.0% and is now trading at $1.67.
View the best growth stocks for 2022 here
.

When is Xeris Biopharma's next earnings date?

Xeris Biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Xeris Biopharma
.

How can I listen to Xeris Biopharma's earnings call?

Xeris Biopharma will be holding an earnings conference call on Wednesday, August 10th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 929-458-6194 with passcode "562978".

How were Xeris Biopharma's earnings last quarter?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) announced its earnings results on Wednesday, May, 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by $0.01. The company had revenue of $22.07 million for the quarter, compared to analyst estimates of $22.92 million. Xeris Biopharma had a negative net margin of 217.81% and a negative trailing twelve-month return on equity of 258.57%.

What other stocks do shareholders of Xeris Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Biopharma investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Miragen Therapeutics (MGEN), Novan (NOVN), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), Cogent Biosciences (UMRX) and OrganiGram (OGI).

When did Xeris Biopharma IPO?

(XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Xeris Biopharma's stock symbol?

Xeris Biopharma trades on the NASDAQ under the ticker symbol "XERS."

Who are Xeris Biopharma's major shareholders?

Xeris Biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include Deltec Asset Management LLC (0.30%), Sinecera Capital LLC (0.19%), AE Wealth Management LLC (0.06%), GPS Wealth Strategies Group LLC (0.05%), ProShare Advisors LLC (0.02%) and Simplex Trading LLC (0.00%). Company insiders that own Xeris Biopharma stock include John Patrick Shannon Jr, Paul R Edick and Steven Prestrelski.
View institutional ownership trends for Xeris Biopharma
.

How do I buy shares of Xeris Biopharma?

Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xeris Biopharma's stock price today?

One share of XERS stock can currently be purchased for approximately $1.67.

How much money does Xeris Biopharma make?

Xeris Biopharma (NASDAQ:XERS) has a market capitalization of $226.34 million and generates $49.59 million in revenue each year. The company earns $-122,720,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis.

How many employees does Xeris Biopharma have?

Xeris Biopharma employs 294 workers across the globe.

How can I contact Xeris Biopharma?

Xeris Biopharma's mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The official website for Xeris Biopharma is www.xerispharma.com. The company can be reached via phone at (844) 445-5704 or via email at ir@xerispharma.com.

This page (NASDAQ:XERS) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.